PRINCETON, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2024 after the market close on Tuesday, May 7th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET.
Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance.
Certara also announced that Company management will participate at the upcoming BofA Securities Healthcare Conference.
Company management will present at 3:40PM PT on Tuesday, May 14th.
Live and archived webcasts of both the financial results conference call and the BofA presentation will be available on the “Investors” section of the Certara website at https://ir.certara.com/.
About Certara
Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,300 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries. Visit us at www.certara.com.
Investor Relations Contact:
David Deuchler
Gilmartin Group
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Pan Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$9.96 |
Daily Change: | -0.57 -5.41 |
Daily Volume: | 1,213,977 |
Market Cap: | US$1.600B |
November 06, 2024 September 18, 2024 August 15, 2024 August 06, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB